Letermovir dosage and administration methods

Letermovir is an effective antiviral drug primarily used to prevent cytomegalovirus (CMV) infection, especially in patients undergoing hematopoietic stem cell transplantation (HSCT) and high-risk kidney transplantation. It has clear indications and can provide protection to patients at risk of CMV infection.

For patients receiving allogeneic hematopoietic stem cell transplantation, letermovir is indicated for adults and children 6 months of age and older and weighing at least 6kg. These patients are usually CMV seropositive and may be at higher risk for CMV infection after transplantation. In addition, letermovir is also suitable for high-risk kidney transplant recipients aged 12 years and above and weighing at least 40kg, especially patients with CMV seropositive donors and CMV seronegative recipients. Both types of patients require prompt use of this drug to reduce the incidence of CMV infection and disease.

In terms of usage and dosage, letermovir is available in three dosage forms: tablets, injections and oral granules. When taking the medicine, the patient can choose to take it on an empty stomach or after a meal, but the tablet must be swallowed whole and must not be broken, crushed or chewed. In addition, when combined with drugs such as cyclosporine, the dose of letermovir needs to be adjusted to ensure efficacy and safety. After completing the preventive treatment course, it is recommended to regularly monitor CMV reactivation in HSCT recipients so that appropriate countermeasures can be taken in a timely manner.

The specific recommended dosage is as follows: For adults and children 12 years and older and weighing at least 30kg who have received allogeneic hematopoietic stem cell transplantation, 480mg should be taken orally daily after surgery, starting on the day after surgery or no later than 28 days after surgery, and continuing until 100 days after transplantation. If the patient is at risk for recent CMV infection and disease, this may need to be extended to 200 days. For patients undergoing kidney transplantation, the dose is also 480 mg daily, starting on the day after surgery or no later than 7 days after surgery, and continuing until 200 days after transplantation.

For HSCT transplant recipients who are over 6 months old and under 12 years old and weigh at least 30kg, the dose is adjusted according to body weight: patients weighing 30kg and above take 480mg orally each time; patients weighing 15kg to 30kg take 480mg orally each time; 240 mg taken orally; patients weighing 7.5kg to 15kg are recommended to take one pack of 120mg oral granules or 60mg intravenous injection per day; while patients weighing 6kg to 7.5kg are recommended to take four packs of 20mg oral granules per day or one 40mg intravenous injection per day.

Overall, letermovir provides an effective prevention method for high-risk patients. Through reasonable medication methods and dosages, the incidence of CMV infection can be significantly reduced. However, patients should always follow the doctor's instructions during use to ensure the safety and effectiveness of the medication. In addition, it is also very important to regularly monitor and evaluate the patient's health status in order to adjust the treatment plan in a timely manner and maximize the treatment effect.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK548861/